NCT07022483 2026-02-04
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
Daiichi Sankyo
Tata Memorial Centre
Leiden University Medical Center
Institut Paoli-Calmettes
Peking Union Medical College Hospital
Merck Sharp & Dohme LLC